[ad_1]
Radnor, Pennsylvania, December 25, 2021 /PRNewswire/ – Law Firm Kessler Topaz Meltzer & Check, LLP Notify investors that Revance Therapeutics, Inc. (“Revance”) (NASDAQ stock code:RVNC). The lawsuit alleges that Revance violated federal securities laws, including omissions and fraudulent misrepresentations related to the company’s business, operations, and prospects. Due to Revance’s material misleading statements to the public, Revance investors suffered heavy losses.
To view our video, please click here
click here Submit your REVANCE loss
Deadline for lead plaintiff: February 8, 2022
class time: November 25, 2019 pass through October 11, 2021
Contact a lawyer to discuss your rights:
James Marlow, Esq. (484) 270-1453 or free (844) 887-9500 or email to info@ktmc.com
REVANCE Suspected misconduct
Revance is a biotechnology company engaged in the development, manufacturing and commercialization of neuromodulators for various cosmetic and therapeutic indications. Revance’s main drug candidate is DaxibotulinumtoxinA for injection (“DAXI”), which has completed phase III clinical trials for the treatment of brow (frowning) lines and cervical dystonia.
exist November 25, 2019, Revance issued a press release announcing that it has submitted a DAXI Biologics License Application (“BLA”) to the FDA.Then, in October 12, 2021, Revance issued a press release, revealing that July 2, 2021, The FDA has issued a 483 form to notify Revance of serious concern about it…
The full story can be found on Benzinga.com
[ad_2]
Source link
